Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140
May 23 2018 - 2:00PM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a
clinical stage biotechnology company, today announced that the
United States Patent and Trademark Office (USPTO) has granted
Oragenics and The Texas A&M University System U.S. Patent No.
9,964,488 titled, “Variants of the Lantibiotic MU1140 and Other
Lantibiotics with Improved Pharmacological Properties and
Structural Features.”
Among other things, the patent covers the unique variants of the
lantibiotic 1140 (MU1140) and other lantibiotics with improved
pharmacological properties and structural features as well as the
methods of using these compositions to treat and prevent
infections, diseases, and colonization by one or more types of
bacteria.
“In recent years, antibiotic resistant bacteria have been on the
rise, affecting millions of people worldwide and resulting in an
increasingly large burden on the healthcare system. Lantibiotics
serve as an important class of antibiotics with the potential to
serve in the treatment of problematic infections caused by
Gram-positive bacteria, while also potentially limiting the
development of drug resistance,” Alan Joslyn, chief executive
officer and president of Oragenics, said. “This patent provides
broad protection for unique variants of MU1140 and other
lantibiotics in our library that will enter IND-enabling studies
for the treatment of antibiotic resistant bacteria.”
James Smith, associate professor in the Department of Biology at
Texas A&M University, said, “Healthcare-associated infections
caused by multi-drug resistant pathogens have become particularly
worrisome. Through our collaborative work, we are pleased that the
granting of this patent will support the continued development of
novel lantibiotics. We are hopeful that we are on a path towards
new antibiotic treatments that have the potential to target this
critical, unmet need in the medical community.”
About Oragenics, Inc.
We are focused on becoming a leader in novel antibiotics against
infectious disease and on developing effective treatments for oral
mucositis. Oragenics, Inc., has established two exclusive worldwide
channel collaborations with Intrexon Corporation (NYSE: XON) and
its subsidiaries. The collaborations allows Oragenics to accelerate
the development of much needed new antibiotics that can work
against resistant strains of bacteria and the development of
biotherapeutics for oral mucositis and other diseases and
conditions of the oral cavity, throat and esophagus.
For more information about Oragenics, please visit
www.oragenics.com.
About the Department of Biology at Texas A&M
University
The Department of Biology is responsible for research and
teaching within the vast disciplines of the biological sciences,
from molecular cell biology to ecology and evolutionary biology.
Our faculty performs cutting-edge research in a wide array of
biological sciences in the laboratory and in the field. Our
graduate research programs prepare scientists for careers in
academia, industry and government, and enhance our understanding of
the central role of biological systems in the global environment.
Our undergraduate students gain a firm foundation in modern
biological sciences to prepare them for a multitude of careers that
depend on a solid understanding of biology.
For more information about the Department of Biology at Texas
A&M University, please visit
http://www.bio.tamu.edu/.
About Research at Texas A&M University: As one
of the world's leading research institutions, Texas A&M is at
the forefront in making significant contributions to scholarship
and discovery, including that of science and technology. Research
conducted at Texas A&M represented annual expenditures of more
than $905.4 million in fiscal year 2017. Texas A&M ranked in
the top 20 of the National Science Foundation’s Higher Education
Research and Development survey (2016), based on expenditures of
more than $892.7 million in fiscal year 2016. Texas A&M’s
research creates new knowledge that provides basic, fundamental and
applied contributions resulting, in many cases, in economic
benefits to the state, nation and world. To learn more,
visit http://research.tamu.edu.
Safe Harbor Statement: Under the Private Securities
Litigation Reform Act of 1995: This release includes
forward-looking statements that reflect management’s current views
with respect to future events and performance. These
forward-looking statements are based on management’s beliefs and
assumptions and information currently available. The words “
believe,” “ expect,” “ anticipate,” “ intend,” “ estimate,” “
project” and similar expressions that do not relate solely to
historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because
they are subject to a variety of risks, uncertainties, and other
factors that could cause actual results to differ materially from
those expressed in any such forward-looking statements. These
factors include, but are not limited to, whether the reverse stock
split will be beneficial to the Company and its shareholders, any
inability to meet the NYSE American continued listing standards in
the future for any reason, and those other factors described in our
filings with the U.S. Securities and Exchange Commission. Any
responsibility to update forward-looking statements is expressly
disclaimed.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180523006227/en/
Oragenics, Inc.Corporate:Michael Sullivan,
813-286-7900chief financial
officermsullivan@oragenics.comorInvestor/Media
Relations:The Ruth GroupTram Bui,
646-536-7035tbui@theruthgroup.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024